Chemiderm

Quick links to important sections

Chemiderm

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Chemiderm

This foundational section provides a clear, high-level overview of the medicine Chemiderm, establishing its core identity, composition, and general purpose as an antifungal agent.

Property Description
Active ingredient Terbinafine Hydrochloride
Form Cream, Cutaneous Spray (Solution), and Tablets
Pharmacological class Allylamine Antifungal Agent
Common use Combating fungal pathogens
Origin Synthetic (Allylamine derivative)

What Type of Medicine is Chemiderm and Its Composition?

Chemiderm is defined as a proprietary medicinal product containing the sole active compound, Terbinafine Hydrochloride, classifying it as a powerful Antifungal Agent. This medicine belongs to the highly effective pharmacological class of allylamine derivatives. Pharmacological studies have clinically recognized the allylamine class for its potent ability to eliminate pathogenic fungi, specifically noting its distinct fungicidal action.

The active component, Terbinafine Hydrochloride, is a high-purity synthetic compound, ensuring reliable and consistent anti-mycotic activity. As a single-ingredient product, Chemiderm focuses on this core substance. A distinctive feature of Terbinafine is its chemical affinity for fatty tissues, which allows it to target and accumulate in the skin, nails, and hair.


Available Forms and General Therapeutic Purpose

Chemiderm is strategically made available in multiple high-level dosage forms, including a Cream, a Cutaneous Spray (Solution), and Tablets. Its general therapeutic purpose is to provide relief by systematically neutralizing the growth and structural integrity of fungal organisms, such as those that cause common skin or nail infections.

The existence of forms for both Topical (Dermatological) administration and Oral (Systemic) administration allows for a versatile approach. The Cream and Cutaneous Spray are used directly on the skin, while the Tablets provide systemic action by having the drug absorbed into the bloodstream. The drug's underlying principle involves the disruption of the vital metabolic pathway known as ergosterol biosynthesis, thereby preventing the pathogen from reproducing and maintaining its cell integrity, which is the basis of its general anti-mycotic benefit.

What side effects are possible with Chemiderm?

Possible side effects and safety information

The safety profile of Chemiderm, which contains Terbinafine Hydrochloride, is formally classified by regulatory authorities, grouping potential effects by frequency and the body system involved. This information is derived from official prescribing documents, such as the FDA Prescribing Information and EMA Summary of Product Characteristics.

Frequency-Classified Adverse Reactions

Adverse reactions are categorized based on documented occurrence rates in clinical use:

  • Very Common (ge 1/10): Reactions frequently affecting the gastrointestinal, nervous, musculoskeletal, and skin systems. These include headache, gastrointestinal disturbances such as diarrhea, dyspepsia, nausea, abdominal pain, rash, urticaria, arthralgia, and myalgia.
  • Common (ge 1/100): Fatigue and dizziness are reported as common general disorders.
  • Rare (ge 1/10,000): Rare but serious effects involve the hepatobiliary system, including hepatic failure, jaundice, and hepatitis.

Documented Systemic and Safety Constraints

Side effects are grouped by system-organ classes, including Hepatobiliary Disorders, Nervous System Disorders, and Blood and Lymphatic System Disorders. Regulatory labels highlight potential serious reactions, such as severe hepatic failure (some cases fatal), severe cutaneous reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), and severe blood disorders (e.g., neutropenia).

Taste disturbance (dysgeusia) and loss of taste (ageusia) are noted effects; regulatory documentation states these often resolve within several weeks after discontinuation of the treatment.

Specific patient population constraints exist. Chemiderm is not recommended for use in individuals with chronic or active severe hepatic impairment. Caution is also specified for use in patients with severely reduced renal impairment (creatinine clearance le 50 mL/min).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding acute overdose with Terbinafine Hydrochloride (Chemiderm) focuses primarily on ingestion of the oral tablet formulation exceeding the prescribed dose. Overdose is generally not associated with severe or life-threatening systemic toxicity.

Documented Clinical Manifestations

Symptoms documented in regulatory labeling are typically mild-to-moderate and include gastrointestinal disturbances such as nausea, diarrhea, and epigastric pain. Central nervous system effects such as headache and dizziness have also been officially reported. No specific population-based differences in overdose risk are explicitly detailed in regulatory overdose sections.

Required Emergency Actions and Management

The regulatory standard requires patients to seek immediate medical attention following the suspected ingestion of a larger-than-prescribed dose. Individuals should contact emergency services or a poison control center for guidance. Since no specific antidote is known, management is officially described as symptomatic and supportive treatment.

To minimize absorption, certain procedures may be considered, including the administration of activated charcoal or gastric lavage. Clinical observation and hospital monitoring may be necessary based on the quantity ingested to ensure stability and symptom resolution.

Therapeutic Uses of Chemiderm

What Chemiderm Treats: Main Uses and Benefits

The core therapeutic application of Chemiderm, containing Terbinafine, is centered on managing and providing symptomatic relief for fungal infections. The medicine is commonly used to help with conditions presenting with systemic or localized discomfort, such as Onychomycosis (nail fungus), Tinea Pedis (athlete's foot), Tinea Cruris (jock itch), and Tinea Corporis (ringworm). It is also considered relevant for Tinea Capitis (scalp ringworm), and may be part of symptomatic management applied in the pediatric population.

The medicine plays a role in managing distressing symptoms that interfere with daily functioning, such as the intense itching, scaling, and redness typical of superficial mycoses. In chronic cases like nail infection, it helps address symptom clusters related to keratinous tissue distortion, and contributes to improved comfort during periods of heightened symptoms.

“The medication is used to help with conditions characterized by periods of heightened symptoms, and supports the patient during difficult episodes by easing distress.”

This assistance supports general well-being during symptomatic phases and is applicable in clinical settings that involve acute or unstable symptom patterns, such as where fungal disease is extensive or when additional management of discomfort is required.


Quick Fact: Relief for Inflammation and Itching

Chemiderm is commonly used in contexts involving inflammatory or irritative states to help ease the overall symptom burden of persistent pruritus and scaling related to dermatophytoses.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Chemiderm

Eligibility for using Chemiderm (Terbinafine Hydrochloride) is strictly determined by regulatory authorities based on the medicine's form and a patient's health status. This information is derived from official governmental prescribing labels, such as the FDA and EMA.

Absolute Contraindications (Must Not Use)

  • Hypersensitivity: Patients with a known allergy to Terbinafine Hydrochloride or any component of the specific formulation must not use the medicine.
  • Active Liver Disease (Oral Tablets): The systemic Oral Tablet form is contraindicated in patients with pre-existing chronic or active hepatic disease.

Conditional and Restricted Use

Population/Condition Eligibility Status (Oral Tablets) Restriction/Limitation
Renal Impairment Not Recommended Creatinine Clearance (CrCl) less than 50 mL/min.
Pregnancy/Lactation Not Recommended Use is restricted due to limited data or excretion into breast milk.
Children Conditional Use is typically established in children ge 4 years; not routinely recommended under 1 year of age.

Topical forms (Cream, Spray) are generally considered lower risk, though caution is still advised, and use on the breast area is prohibited during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Systemic drug interactions are associated with the oral tablet formulation of Chemiderm (Terbinafine). The topical forms (cream and cutaneous spray) have minimal systemic absorption and are documented to have no known systemic interaction profile.

Official Interaction Statements

  • CYP2D6 Inhibition: Terbinafine is officially documented as an inhibitor of the CYP2D6 enzyme. This can substantially increase the systemic exposure of co-administered drugs metabolized by this pathway, including certain classes of antidepressants and beta-blockers. For example, Terbinafine reduces the clearance of Desipramine by 82%.
  • Clearance Modification: The plasma concentration of Terbinafine itself is altered by other agents. Rifampicin dramatically increases Terbinafine clearance by 100%, while Cimetidine decreases clearance by 33%. Fluconazole also significantly increases Terbinafine exposure.
  • Substance-Specific Effects: Terbinafine decreases the clearance of Caffeine by 19% and increases the clearance of Cyclosporine by 15%.
  • Observed Effects: Cases of menstrual disturbance have been reported in patients taking oral Terbinafine concomitantly with oral contraceptives, although the official incidence remains within the background rate.
  • Anticoagulants: Rare reports of changes in INR or prothrombin time have been noted with the co-administration of Terbinafine and Warfarin.

Population-Specific Restrictions

Official regulatory labels state that the oral formulation is not recommended for use in patients with pre-existing chronic or active hepatic disease. Use is also not recommended in patients with severe renal impairment (creatinine clearance < 50 mL/min).

Mechanism of Action

Targeted Inhibition of Fungal Sterol Synthesis

The mechanism of action engages the domain of fungal enzyme inhibition. It acts as a non-competitive inhibitor of Fungal Squalene Epoxidase, an enzyme crucial to the early stages of the ergosterol biosynthesis pathway. This action prevents the pathogen from producing ergosterol, the primary sterol component of the fungal cell membrane.


Dual Cellular Toxicity and Lysis

By blocking the conversion of squalene, the drug initiates a mechanistic cascade. This leads to simultaneous impairment of Fungal Cell Membrane Integrity through two resulting physiological effects: a critical deficiency of ergosterol and the accumulation of squalene to toxic concentrations inside the fungal cell. The resulting damage causes the cell membrane to become highly permeable and rupture (lysis), which defines the drug's fungicidal action against the pathogenic organism.


Mechanism-Sustaining Tissue Concentration

The drug's high lipophilicity defines the domain of tissue affinity. This property facilitates the concentration and retention of the drug within keratinous tissues (skin, hair, and nails) where the fungus resides. This sustained, localized presence allows the fungicidal mechanism to act over an extended period.

Dosage and Administration Information

How to Use Chemiderm: Official Administration Guidelines

Chemiderm (terbinafine) is administered via two primary routes: Oral (systemic) and Topical (dermatological), determined by the location and extent of the fungal infection. The standard administration guidelines, including dosage and frequency, are established for consistent use.


Standard Adult Dosing and Duration

Parameter Oral Administration (Tablets) Topical Administration (Cream/Spray)
Dose and Frequency 250 mg once daily Apply a thin layer once or twice daily
Fingernail Duration 6 weeks Not applicable
Toenail Duration 12 weeks Not applicable
Skin Duration Not applicable Typically 1 to 4 weeks

Administration Context and Adjustments

Oral Chemiderm tablets may be taken with or without food. For the pediatric population requiring systemic treatment, a weight-based dose is administered as oral granules, which must be mixed with soft, non-acidic foods, and not with fruit-based foods.

Specific constraints on use are established. The oral form is generally not recommended for patients with specific levels of renal impairment (creatinine clearance less than 50 mL/min) and is contraindicated in patients with chronic or active liver disease. Topical forms are strictly for external use only and should not be applied to mucous membranes or ingested.

Recent Clinical Evidence

Research evidence / Overview of studies for Chemiderm

The research evidence for Chemiderm (Terbinafine) primarily comes from official clinical trials and comprehensive reviews that have explored its use in various fungal skin and nail infections. These studies describe what has been observed so far in controlled research settings.


Evidence for Use in Onychomycosis (Nail Fungus)

Research for nail fungus is heavily based on Randomized Controlled Trials (RCTs) and systematic reviews. Because nails grow slowly, the studies exploring Chemiderm’s use for this condition were typically long-term, often requiring participants to be observed for 48 to 72 weeks to observe the study outcomes. These trials examined the mycological cure (fungal elimination) and the clinical cure (changes related to nail appearance).

Research highlights changes measured during the study period related to the nail structure and documented the proportion of participants achieving a specified clinical cure endpoint. Studies also reported patterns related to recurrence following the discontinuation of the study intervention.

Long-term outcomes are not fully established. While follow-up is long, studies provide limited insight into the very long-term maintenance of nail clearance. Additionally, variability in reported outcomes was observed in some studies.


Evidence for Use in Superficial Skin Infections (Tinea Pedis, Cruris, and Corporis)

Evidence related to common superficial skin infections like Athlete's Foot and Ringworm is derived from short-term Randomized Controlled Trials (RCTs). These studies primarily explore topical Chemiderm and often compare its performance to a placebo or other established antifungal treatments. The research examined mycological cure status and outcomes related to visible symptoms, such as scaling, redness, and patient-reported outcomes describing perceived discomfort.

Studies explored comparisons of observed outcomes between the study intervention and the control group, reporting various rates of both mycological elimination and symptom change within the study periods. Research provides insight into short-term changes, but there is limited characterization of the medicine’s association with long-term patterns of recurrence after the initial course of treatment has been completed.

Frequently Asked Questions (FAQ)

Common questions about Chemiderm (FAQ)


Q: Is Chemiderm a steroid, or does it have steroids in it?

Official product information states that Chemiderm's active ingredient, Terbinafine Hydrochloride, belongs to the allylamine class of antifungal agents. It is not classified as a steroid, but as a medication that works by directly disrupting fungal cell integrity.


Q: How fast should I expect Chemiderm to start working?

Regulatory documents indicate that the total treatment duration for common skin infections is typically 1 to 4 weeks. The time it takes to see visible improvement can vary, as results depend on the specific infection type and severity. Nail infections, in particular, require several months to observe the full result due to the slow growth rate of the nail.


Q: What is the difference between Chemiderm and other topical creams for the same condition?

Chemiderm is an allylamine antifungal that works by targeting the fungal enzyme squalene epoxidase. This mechanism damages the fungal cell membrane, which results in the death of the cell (a fungicidal effect). This specific action distinguishes it from other general classes of antifungal creams, such as the azole antifungals.


Q: Will Chemiderm still work if I miss an application?

Official patient instructions state that if an application of topical Chemiderm is missed, it should be applied as soon as it is remembered, then the regular schedule should be continued. For oral tablets, it is advised not to double up on doses to make up for a missed one. Consistency is important for effectiveness, and the specific directions provided should be followed.


Q: Does Chemiderm have a risk of systemic absorption?

The oral tablet form is absorbed into the bloodstream and is designed for systemic absorption (internal action). The topical forms (cream and spray), however, are poorly absorbed into the systemic circulation. This means the topical forms have only minimal exposure to the rest of the body.


Q: Is it safe to use Chemiderm if I have other medical conditions like diabetes?

Regulatory documents list specific restrictions, particularly for the oral form, for people with pre-existing chronic or active hepatic (liver) disease and severe renal (kidney) impairment. Official information does not restrict use based on other common conditions like diabetes. However, a healthcare provider should review all pre-existing conditions before starting treatment.


Q: Do I need to wash my hands immediately after applying Chemiderm?

Yes, official product instructions strongly advise washing your hands thoroughly immediately after applying the topical medication. This is an important measure to prevent the medicine from being unintentionally spread to other parts of your body or to sensitive areas like your eyes, unless the area being treated is the hands themselves.


Q: Is Chemiderm supposed to be rubbed in completely or left on the surface?

The instructions for the topical form state to apply a thin layer of the product to the affected area and the immediate surrounding skin. While you should spread it evenly to cover the area, official labeling does not specifically direct users to rub it in until the product is completely absorbed and invisible.


Q: What kind of moisturizer is safe to use along with Chemiderm?

The topical product has minimal systemic absorption and no documented systemic interactions. Official information does not provide a list of specific non-medicated moisturizers that are safe to use concurrently. Therefore, you should consult the patient instructions for guidance on applying other topical products.


Q: Can Chemiderm cause long-term skin changes like thinning or discoloration?

Common side effects for the topical form are localized to the application site and include temporary irritation, burning, and dryness. While rare, severe skin reactions have been reported with the oral form. Long-term skin changes like atrophy (thinning) or discoloration are not listed as common side effects in the official topical safety profile.


Q: Can Chemiderm be used on sensitive areas like the face or groin?

Topical Chemiderm is indicated for fungal infections in the groin area (tinea cruris). However, official labeling generally advises against applying the topical product to highly sensitive areas like the eyes, inside the mouth or nose, or directly on the scalp unless specifically advised by a healthcare professional.


Q: Is it normal to feel a tingling or burning sensation right after applying Chemiderm?

Official regulatory documents list that common side effects reported with the topical form include temporary burning, stinging, and irritation at the site of application. These local reactions are typically mild and may occur in some users. If the irritation becomes severe or does not go away, contact a healthcare provider.


Q: Can I apply makeup or other skin products over Chemiderm?

Official instructions direct users to clean and dry the affected skin before applying Chemiderm. Applying other products, such as makeup, over the medication is not specifically covered in regulatory patient information, and using other products over the medication may interfere with its intended effect or absorption.


Q: What happens if I accidentally put too much Chemiderm on?

Official warnings state that for topical forms, using the product more often or longer than directed may increase the risk of localized side effects like irritation. Overdose from the oral tablets may cause systemic symptoms, such as headache, nausea, and dizziness, and severe symptoms should be reported to a healthcare professional immediately.


Q: What should I do if my skin gets worse after starting Chemiderm?

Official patient instructions advise stopping use if too much irritation, redness, or itching occurs, or if your symptoms appear to get worse. If severe side effects or allergic reactions develop, seeking immediate medical assistance is required.


Q: Are there any food or drink restrictions while using Chemiderm?

The oral tablet can be taken with or without food. Official regulatory documents indicate that the oral drug can affect the clearance of caffeine in the body. Additionally, some patient information sources suggest caution or discussion with a healthcare provider regarding alcohol use during treatment with the oral form.


Q: Is the vehicle (cream/lotion base) of Chemiderm known to cause allergies?

Official documents state that the medicine is contraindicated if there is a known allergy to the active ingredient, Terbinafine Hydrochloride, or to any other component of the specific product formulation. The full list of inactive ingredients (the vehicle) that could cause allergies is detailed in the official product label.


Q: Can applying Chemiderm cause peeling or flaking?

Yes, common side effects reported with the topical forms include localized reactions such as exfoliation (peeling) and dryness at the application site. These are typically expected reactions that indicate the skin is responding to the medication.


Q: Is Chemiderm a treatment or just a way to manage symptoms?

Chemiderm is classified as a fungicidal agent, meaning its primary action is to eliminate the fungal organism by disrupting its cell structure. The official mechanism of action involves damaging the fungal cell membrane, thereby working to eliminate the infection rather than simply masking the symptoms.


Q: How long do the effects of Chemiderm typically last after stopping use?

The drug is known for its high affinity for keratinous tissues (skin and nails). The oral form has a long terminal half-life, meaning it is retained in these tissues for an extended period after treatment stops. This sustained presence in the affected area is thought to contribute to the prevention of infection recurrence.

How should Chemiderm be stored and disposed of?

Storage and Disposal Requirements

All storage and disposal instructions for Chemiderm must be followed exactly as stated in the official regulatory labeling to maintain product stability and safety.

Official Storage Conditions

Requirement Standard Condition
Temperature Range Store at controlled room temperature, typically 20 C to 25 C.
Protection Topical forms must not be frozen. Tablets must be protected from moisture.
Container Rule Keep the medicine in its original container, often requiring a tightly closed seal for tablets.
Child Safety The product must be kept strictly out of the sight and reach of children.

Disposal of Unused Product

Expired or unused Chemiderm should be disposed of according to local regulatory requirements. Medicines must not be thrown away via wastewater (e.g., flushed down the toilet). The recommended household disposal procedure for non-flushable medicines involves mixing the product with an undesirable substance (such as coffee grounds) and placing the mixture in a sealed bag before putting it in the household trash. Any unused cream must be discarded after the treatment course is complete.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Chemiderm found in:

A-Z Index: